Erschienen in:
13.09.2017 | Letter
SGLT2 inhibitors and cancer: why further evidence is required
verfasst von:
Altamash M. Y. Shaikh
Erschienen in:
Diabetologia
|
Ausgabe 12/2017
Einloggen, um Zugang zu erhalten
Excerpt
To the Editor: The article on sodium–glucose cotransporter 2 (SGLT2) inhibitors and cancers by Tang et al [
1], which was recently published in
Diabetologia, is very relevant to practice in today’s world. However, this letter is to bring to your kind attention an error in this article. Tang and colleagues conducted a meta-analysis of RCTs to identify any risk of cancer with SGLT2 inhibitors. The results suggested a possible increased risk of bladder cancer with empagliflozin therapy. We noted a possible error in the paper, as discussed below. …